Predicting pregnancy complications with high-plex proteomics
A SomaLogic boutique webinar
Predicting pregnancy complications with high-plex proteomics
The interdisciplinary team, comprising 10-15 scientists and clinician-scientists, is dedicated to advancing diagnostics and therapeutics aimed at enhancing maternal and fetal care. Their primary focus lies in the development of interventions for conditions such as ectopic pregnancy and preeclampsia, alongside the creation of diagnostics to prevent stillbirth. In this webinar, Dr. Lucy Bartho delves into the transformative role of SomaLogic’s SomaScan® assay in their biomarker discovery endeavors. She will also elaborate on how this technology has facilitated the development of clinical tools for the early identification of preeclampsia and fetal growth restriction.
Lucy Bartho, PhD
Dr. Lucy Bartho is a postdoctoral fellow from the Translational Obstetrics Group at the University of Melbourne, co-led by Professor Stephen Tong and Professor Tu’uhevaha Kaitu’u-Lino. The team of 10-15 scientists and clinician-scientists is dedicated to developing diagnostics and therapeutics aimed at enhancing the care of pregnant women and their fetuses. The research arising from the team focuses on identifying novel biomarkers for predicting pregnancy complications, developing treatments for ectopic pregnancy and preeclampsia, and elucidating the pathogenesis of these conditions.
Predicting pregnancy complications with high-plex proteomics
A presentation by Lucy Bartho, PhD
More webinars
WebinarPathways to Digital Health: AI and Omics in Rheumatoid Arthritis
Explore how groundbreaking proteomic research is transforming our understanding of rheumatoid arthritis (RA). In this on-demand webinar, Allan Stensballe, PhD, shares new insights into the molecular landscape of RA-affected synovial tissue, revealing how autoantibodies and protein signatures may hold the key to more precise personalized therapies.
WebinarUsing Antibody Profiling to Identify Novel Diagnostic Biomarkers
Current cancer screening methods often lead to false positives, false negatives and invasive biopsies that lack prognostic insights. Emerging research suggests that cancer-specific IgM and IgG antibodies – produced by B cells upon recognizing malignant cells – could serve as stable, easily measurable blood biomarkers for detecting and monitoring high-incidence cancers like melanoma and breast, prostate, bowel, lung and pancreatic cancer. This approach has the potential to improve early diagnosis, reduce uncertainty and enhance treatment planning.
WebinarLinking the plasma proteome to echocardiographic parameters in patients with chronic heart failure
Recent advancements in proteomic profiling have unlocked new possibilities for understanding the complex mechanisms that drive heart failure. Measuring thousands of proteins simultaneously makes it possible to capture a comprehensive overview of the patient's health state and investigate underlying disease progression at a subclinical level.